Related references
Note: Only part of the references are listed.Evaluation of imidazo[2,1-b]thiazole-based anticancer agents in one decade (2011-2020): Current status and future prospects
Rawan M. Sbenati et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2021)
Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells
Rawan M. Sbenati et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Discovery of New Imidazo[2,1-b]thiazole Derivatives as Potent Pan-RAF Inhibitors with Promising In Vitro and In Vivo Anti-melanoma Activity
Mohammed S. Abdel-Maksoud et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Imidazothiazole-based potent inhibitors of V600E-B-RAF kinase with promising anti-melanoma activity: biological and computational studies
Hanan S. Anbar et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2020)
Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives
Daniele Lavacchi et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2019)
Discovery of highly potent V600E-B-RAF kinase inhibitors: Molecular modeling study
Hamadeh Tarazi et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2019)
Ibrutinib inhibition of ERBB4 reduces cell growth in a WNT5A-dependent manner
Femina Rauf et al.
ONCOGENE (2018)
Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
Tae Min Kim et al.
CANCER RESEARCH AND TREATMENT (2018)
Neratinib, A Novel HER2-Targeted Tyrosine Kinase Inhibitor
Shruti Rakesh Tiwari et al.
CLINICAL BREAST CANCER (2016)
ERBB4 is over-expressed in human colon cancer and enhances cellular transformation
Christopher S. Williams et al.
CARCINOGENESIS (2015)
Design, synthesis, in vitro antiproliferative evaluation, and kinase inhibitory effects of a new series of imidazo[2,1-b]thiazole derivatives
Mohammed S. Abdel-Maksoud et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2015)
Convergent and Divergent Cellular Responses by ErbB4 Isoforms in Mammary Epithelial Cells
Vikram B. Wali et al.
MOLECULAR CANCER RESEARCH (2014)
A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer
Helmout Modjtahedi et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2014)
Cytochrome P450 3A4 Inhibition by Ketoconazole: Tackling the Problem of Ligand Cooperativity Using Molecular Dynamics Simulations and Free-Energy Calculations
Urban Bren et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2012)
New imidazo[2,1-b]thiazole derivatives: Synthesis, in vitro anticancer evaluation, and in silico studies
Jin-Hun Park et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2011)
Mechanism of cytochrome P450-3A inhibition by ketoconazole
David J. Greenblatt et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2011)
Catalytic Control in the EGF Receptor and Its Connection to General Kinase Regulatory Mechanisms
Natalia Jura et al.
MOLECULAR CELL (2011)
AST1306, A Novel Irreversible Inhibitor of the Epidermal Growth Factor Receptor 1 and 2, Exhibits Antitumor Activity Both In Vitro and In Vivo
Hua Xie et al.
PLOS ONE (2011)
ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer
David F. Stern
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2008)
TheEGF receptor family: spearheading a merger of signaling and therapeutics
Erez M. Bublil et al.
CURRENT OPINION IN CELL BIOLOGY (2007)
Coregulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine signal in breast tumor cells
Yun Zhu et al.
CANCER RESEARCH (2006)
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
Xuewu Zhang et al.
CELL (2006)
The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer
J Edwards et al.
CLINICAL CANCER RESEARCH (2006)
Small molecules with EGFR-TK inhibitor activity
J Albanell et al.
CURRENT DRUG TARGETS (2005)
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells
ER Wood et al.
CANCER RESEARCH (2004)
IonWorks™ HT:: A new high-throughput electrophysiology measurement platform
K Schroeder et al.
JOURNAL OF BIOMOLECULAR SCREENING (2003)
ST1571 (Gleevec (TM)) as a paradigm for cancer therapy
BJ Druker
TRENDS IN MOLECULAR MEDICINE (2002)
The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications - Report on a Policy Conference of the European Society of cardiology
W Haverkamp et al.
EUROPEAN HEART JOURNAL (2000)
Tyrosine kinase inhibitors.: 17.: Irreversible inhibitors of the epidermal growth factor receptor:: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions
JB Smaill et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Share Paper
